Bajaj Healthcare

Market Cap: Small Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE411U01027
NSEID: BAJAJHCARE
BSEID: 539872

INR

420.50

-3.45 (-0.81%)

BSENSE

Dec 05

BSE+NSE Vol: 38.96 k

{
  "main_header": {
    "sid": 1002590,
    "name": "Bajaj Healthcare",
    "stock_name": "Bajaj Healthcare",
    "full_name": "Bajaj Healthcare Ltd",
    "name_url": "stocks-analysis/bajaj-healthcare",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "420.50",
    "chg": -3.45,
    "chgp": "-0.81%",
    "dir": -1,
    "prev_price": "423.95",
    "mcapval": "1,333.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 539872,
    "symbol": "BAJAJHCARE",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE411U01027",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "38.96 k",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/bajaj-healthcare-1002590-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Why is Bajaj Healthcare falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-bajaj-healthcare-fallingrising-3745010",
        "imagepath": "",
        "date": "2025-12-04 00:52:08",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Performance and Market Context</strong></p>\n<p>Bajaj Healthcare’s stock has been under pressure in recent sessions, recording a consecutive three-day decline that has resulted in a cumulative loss of 2.51%. This underperformance is also evident when compared to its sector peers, with the stock lagging by 0.67% today. The current price is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a bearish technical outlook.</p>\n<p>Over the short term, the stock’s returns have been disappointing. In the past month, Bajaj Healthcare has declined by 10.78%, contrasting sharply with the Sensex’s 1.34% gain over the same period. Year-to-date, the stock has fallen 27.36%, while the benchmark index has advanced by 8.92%. Althou..."
      },
      {
        "title": "Is Bajaj Healthcare technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-bajaj-healthcare-technically-bullish-or-bearish-3740528",
        "imagepath": "",
        "date": "2025-12-02 09:11:22",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Technical Trend Shift and Moving Averages</strong></p>\n<p>As of 01 Dec 2025, Bajaj Healthcare's technical trend has shifted from mildly bearish to outright bearish. This transition reflects increasing selling pressure and a weakening price structure. The daily moving averages, a critical gauge of short-term momentum, remain firmly bearish, indicating that the stock price is trading below its average levels and suggesting a continuation of downward momentum in the near term.</p>\n<p><strong>Momentum Indicators: MACD and KST Analysis</strong></p>\n<p>The Moving Average Convergence Divergence (MACD) indicator, widely used to assess trend strength and direction, presents a bearish signal on the weekly chart and a mildly bearish stance on the monthly timeframe. This divergence implies that while th..."
      },
      {
        "title": "Bajaj Healthcare Evaluation Revised Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/bajaj-healthcare-downgraded-to-strong-sell-amid-technical-weakness-and-long-term-challenges-3740720",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BajajHealthcare_mojoScore_3740720.png",
        "date": "2025-12-02 08:47:35",
        "description": "Bajaj Healthcare, a key player in the Pharmaceuticals & Biotechnology sector, has undergone a revision in its market assessment following a detailed analysis of its financial performance, valuation metrics, and technical indicators. The recent changes reflect a nuanced view of the company’s prospects amid a challenging industry backdrop and evolving market dynamics."
      },
      {
        "title": "Bajaj Healthcare Technical Momentum Shifts Amid Bearish Indicators",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/bajaj-healthcare-technical-momentum-shifts-amid-bearish-signals-3740296",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/BajajHealthcare_technicaldot_3740296.png",
        "date": "2025-12-02 08:10:41",
        "description": "Bajaj Healthcare’s recent market activity reveals a shift in technical momentum, with several key indicators signalling a bearish trend. The stock’s price movement, combined with changes in momentum oscillators and moving averages, suggests a cautious outlook for investors in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "How has been the historical performance of Bajaj Healthcare?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-bajaj-healthcare-3739320",
        "imagepath": "",
        "date": "2025-12-01 23:24:30",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Profit Trends</strong></p>\n<p>Over the seven-year period ending March 2025, Bajaj Healthcare’s net sales demonstrated considerable volatility. The company’s revenue peaked in fiscal 2022 at nearly ₹680 crores before contracting to ₹543 crores in 2025. This decline followed a sharp dip in fiscal 2024, where sales dropped to ₹473 crores from ₹646 crores in 2023. Despite these fluctuations, the firm maintained a generally upward trajectory compared to the ₹370 crores recorded in 2019.</p>\n<p>Operating profit margins, excluding other income, have also seen a downward trend from a high of 20.75% in 2021 to 15.19% in 2025. This contraction reflects rising costs and operational pressures. The operating profit itself peaked at ₹143 crores in 2021 but fell to approximately ₹82 crores by 2..."
      },
      {
        "title": "Bajaj Healthcare Sees Revision in Market Evaluation Amid Mixed Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/bajaj-healthcare-upgraded-from-strong-sell-to-sell-by-marketsmojo-3737063",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/BajajHealthcare_mojoScore_3737063.png",
        "date": "2025-11-30 10:24:53",
        "description": "Bajaj Healthcare’s market evaluation has undergone a revision reflecting nuanced changes in its financial and technical outlook. The pharmaceutical and biotechnology company, classified as a small-cap, has experienced shifts in key assessment parameters that influence investor perception and market positioning."
      },
      {
        "title": "How has been the historical performance of Bajaj Healthcare?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-bajaj-healthcare-3695473",
        "imagepath": "",
        "date": "2025-11-13 00:26:15",
        "description": "Answer:\nThe historical performance of Bajaj Healthcare shows significant fluctuations in key financial metrics over the years.\n\nBreakdown:\nBajaj Healthcare's net sales have varied, peaking at 645.80 Cr in Mar'23 before declining to 542.60 Cr in Mar'25. Total operating income followed a similar trend, with a high of 679.89 Cr in Mar'22, dropping to 542.60 Cr in Mar'25. Raw material costs increased from 291.33 Cr in Mar'19 to 307.11 Cr in Mar'25, while total expenditure (excluding depreciation) rose from 327.55 Cr in Mar'19 to 460.17 Cr in Mar'25. Operating profit (PBDIT) saw a decline from 143.23 Cr in Mar'21 to 101.83 Cr in Mar'25, with a corresponding decrease in profit before tax from 118.82 Cr in Mar'21 to 46.01 Cr in Mar'25. Profit after tax also fluctuated, reaching a high of 83.11 Cr in Mar'21 but falling to 42.93 Cr in Mar'25. The company's total assets increased from 342.95 Cr in Mar'20 to 814.15 Cr..."
      },
      {
        "title": "Is Bajaj Healthcare overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-bajaj-healthcare-overvalued-or-undervalued-3684196",
        "imagepath": "",
        "date": "2025-11-10 08:12:41",
        "description": "As of 7 November 2025, Bajaj Healthcare's valuation grade has moved from fair to expensive, indicating a shift in its perceived market value. The company is currently overvalued based on its financial metrics. Key ratios include a PE ratio of 27.28, an EV to EBITDA of 18.91, and a PEG ratio of 0.83, which suggests that while the company is growing, its valuation may not be justified by its earnings growth prospects.\n\nIn comparison to its peers, Bajaj Healthcare's PE ratio is notably higher than Cipla's 22.33, which is rated attractive, and Dr. Reddy's Labs at 17.43, also attractive. This indicates that Bajaj Healthcare is trading at a premium relative to these competitors despite not offering a significantly better growth outlook. Additionally, the stock has underperformed against the Sensex in the year-to-date period, with a return of -24.7% compared to the Sensex's 6.50%, further reinforcing the notion th..."
      },
      {
        "title": "How has been the historical performance of Bajaj Healthcare?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-bajaj-healthcare-3683560",
        "imagepath": "",
        "date": "2025-11-09 22:42:14",
        "description": "Answer:\nThe historical performance of Bajaj Healthcare shows fluctuations in key financial metrics over the years, with notable changes in revenue and profitability.\n\nBreakdown:\nBajaj Healthcare's net sales peaked at 679.89 Cr in March 2022 but have since declined to 542.60 Cr in March 2025, reflecting a downward trend in total operating income, which also decreased from 645.80 Cr in March 2023 to 542.60 Cr in March 2025. The raw material costs have varied, with a significant drop from 393.84 Cr in March 2023 to 307.11 Cr in March 2025. Operating profit, excluding other income, has shown a decline from 136.32 Cr in March 2021 to 82.43 Cr in March 2025. The profit before tax turned negative in March 2024 at -16.68 Cr but rebounded to 46.01 Cr in March 2025. Profit after tax also saw a recovery from -14.33 Cr in March 2024 to 42.93 Cr in March 2025. The company's total assets increased from 721.10 Cr in March..."
      }
    ],
    "total": 225,
    "sid": "1002590",
    "stock_news_url": "https://www.marketsmojo.com/news/bajaj-healthcare-1002590"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "03-Dec-2025",
      "details": "Intimation of schedule of Analyst/ Institutional Investor Meetings under the SEBI (LODR) Regulations 2015",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
      "datetime": "27-Nov-2025",
      "details": "Appointment of Chief Operating Officer Senior Management Personnel of the Company",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
      "datetime": "21-Nov-2025",
      "details": "Appointment of Additional Director (Non-Executive Independent Director Category)",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Bajaj Healthcare Ltd has declared <strong>20%</strong> dividend, ex-date: 19 Sep 25",
          "dt": "2025-09-19",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Bajaj Healthcare Ltd has announced <strong>5:10</strong> stock split, ex-date: 28 Sep 21",
          "dt": "2021-09-28",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Bajaj Healthcare Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 09 Apr 19",
          "dt": "2019-04-09",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Why is Bajaj Healthcare falling/rising?

2025-12-04 00:52:08

Recent Price Performance and Market Context

Bajaj Healthcare’s stock has been under pressure in recent sessions, recording a consecutive three-day decline that has resulted in a cumulative loss of 2.51%. This underperformance is also evident when compared to its sector peers, with the stock lagging by 0.67% today. The current price is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a bearish technical outlook.

Over the short term, the stock’s returns have been disappointing. In the past month, Bajaj Healthcare has declined by 10.78%, contrasting sharply with the Sensex’s 1.34% gain over the same period. Year-to-date, the stock has fallen 27.36%, while the benchmark index has advanced by 8.92%. Althou...

Is Bajaj Healthcare technically bullish or bearish?

2025-12-02 09:11:22

Technical Trend Shift and Moving Averages

As of 01 Dec 2025, Bajaj Healthcare's technical trend has shifted from mildly bearish to outright bearish. This transition reflects increasing selling pressure and a weakening price structure. The daily moving averages, a critical gauge of short-term momentum, remain firmly bearish, indicating that the stock price is trading below its average levels and suggesting a continuation of downward momentum in the near term.

Momentum Indicators: MACD and KST Analysis

The Moving Average Convergence Divergence (MACD) indicator, widely used to assess trend strength and direction, presents a bearish signal on the weekly chart and a mildly bearish stance on the monthly timeframe. This divergence implies that while th...

Bajaj Healthcare Evaluation Revised Amid Mixed Financial and Technical Signals

2025-12-02 08:47:35

Bajaj Healthcare, a key player in the Pharmaceuticals & Biotechnology sector, has undergone a revision in its market assessment following a detailed analysis of its financial performance, valuation metrics, and technical indicators. The recent changes reflect a nuanced view of the company’s prospects amid a challenging industry backdrop and evolving market dynamics.

Bajaj Healthcare Technical Momentum Shifts Amid Bearish Indicators

2025-12-02 08:10:41

Bajaj Healthcare’s recent market activity reveals a shift in technical momentum, with several key indicators signalling a bearish trend. The stock’s price movement, combined with changes in momentum oscillators and moving averages, suggests a cautious outlook for investors in the Pharmaceuticals & Biotechnology sector.

How has been the historical performance of Bajaj Healthcare?

2025-12-01 23:24:30

Revenue and Profit Trends

Over the seven-year period ending March 2025, Bajaj Healthcare’s net sales demonstrated considerable volatility. The company’s revenue peaked in fiscal 2022 at nearly ₹680 crores before contracting to ₹543 crores in 2025. This decline followed a sharp dip in fiscal 2024, where sales dropped to ₹473 crores from ₹646 crores in 2023. Despite these fluctuations, the firm maintained a generally upward trajectory compared to the ₹370 crores recorded in 2019.

Operating profit margins, excluding other income, have also seen a downward trend from a high of 20.75% in 2021 to 15.19% in 2025. This contraction reflects rising costs and operational pressures. The operating profit itself peaked at ₹143 crores in 2021 but fell to approximately ₹82 crores by 2...

Bajaj Healthcare Sees Revision in Market Evaluation Amid Mixed Financial Signals

2025-11-30 10:24:53

Bajaj Healthcare’s market evaluation has undergone a revision reflecting nuanced changes in its financial and technical outlook. The pharmaceutical and biotechnology company, classified as a small-cap, has experienced shifts in key assessment parameters that influence investor perception and market positioning.

How has been the historical performance of Bajaj Healthcare?

2025-11-13 00:26:15

Answer: The historical performance of Bajaj Healthcare shows significant fluctuations in key financial metrics over the years. Breakdown: Bajaj Healthcare's net sales have varied, peaking at 645.80 Cr in Mar'23 before declining to 542.60 Cr in Mar'25. Total operating income followed a similar trend, with a high of 679.89 Cr in Mar'22, dropping to 542.60 Cr in Mar'25. Raw material costs increased from 291.33 Cr in Mar'19 to 307.11 Cr in Mar'25, while total expenditure (excluding depreciation) rose from 327.55 Cr in Mar'19 to 460.17 Cr in Mar'25. Operating profit (PBDIT) saw a decline from 143.23 Cr in Mar'21 to 101.83 Cr in Mar'25, with a corresponding decrease in profit before tax from 118.82 Cr in Mar'21 to 46.01 Cr in Mar'25. Profit after tax also fluctuated, reaching a high of 83.11 Cr in Mar'21 but falling to 42.93 Cr in Mar'25. The company's total assets increased from 342.95 Cr in Mar'20 to 814.15 Cr...

Is Bajaj Healthcare overvalued or undervalued?

2025-11-10 08:12:41

As of 7 November 2025, Bajaj Healthcare's valuation grade has moved from fair to expensive, indicating a shift in its perceived market value. The company is currently overvalued based on its financial metrics. Key ratios include a PE ratio of 27.28, an EV to EBITDA of 18.91, and a PEG ratio of 0.83, which suggests that while the company is growing, its valuation may not be justified by its earnings growth prospects. In comparison to its peers, Bajaj Healthcare's PE ratio is notably higher than Cipla's 22.33, which is rated attractive, and Dr. Reddy's Labs at 17.43, also attractive. This indicates that Bajaj Healthcare is trading at a premium relative to these competitors despite not offering a significantly better growth outlook. Additionally, the stock has underperformed against the Sensex in the year-to-date period, with a return of -24.7% compared to the Sensex's 6.50%, further reinforcing the notion th...

How has been the historical performance of Bajaj Healthcare?

2025-11-09 22:42:14

Answer: The historical performance of Bajaj Healthcare shows fluctuations in key financial metrics over the years, with notable changes in revenue and profitability. Breakdown: Bajaj Healthcare's net sales peaked at 679.89 Cr in March 2022 but have since declined to 542.60 Cr in March 2025, reflecting a downward trend in total operating income, which also decreased from 645.80 Cr in March 2023 to 542.60 Cr in March 2025. The raw material costs have varied, with a significant drop from 393.84 Cr in March 2023 to 307.11 Cr in March 2025. Operating profit, excluding other income, has shown a decline from 136.32 Cr in March 2021 to 82.43 Cr in March 2025. The profit before tax turned negative in March 2024 at -16.68 Cr but rebounded to 46.01 Cr in March 2025. Profit after tax also saw a recovery from -14.33 Cr in March 2024 to 42.93 Cr in March 2025. The company's total assets increased from 721.10 Cr in March...

View All News